Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Diagnostic accuracy of stool Xpert MTB/RIF assay for adult pulmonary tuberculosis: a systematic review and meta-analysis.

BMC infectious diseases·2026

Same author

A population-based retrospective machine learning study of COVID-19 severity using integrated clinical and viral genomic data in Jiangsu Province, China.

BMC microbiology·2026

Same author

Single nucleotide variant in coenzyme Q6 reprograms macrophage metabolic remodeling in response to inflammatory signals.

Research square·2026

Same author

Serum metabolomic signatures integrating sphingosine-1-phosphate and tetrahydrocortisone improve prognostic assessment in non-ischemic cardiomyopathy.

Metabolomics : Official journal of the Metabolomic Society·2026

Same author

Deep eutectic solvent extraction and AB-8 resin adsorption for rambutan shell polyphenol: Profiling and bioactivity assessments.

Food chemistry: X·2026

Same author

Regulation of H-type angiogenesis and permeability in the subchondral bone of osteoarthritis: the role of Slit3 and the Robo4/Rac1-GTP/ROS axis.

Frontiers in cell and developmental biology·2026

Search research articles

Related Experiment Video

Updated: Dec 25, 2025

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Pharmaceutical Treatment for Heart Failure.

Xue Lin¹, Ligang Fang²

¹Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Advances in Experimental Medicine and Biology

|April 5, 2020

Summary

This review summarizes current pharmaceutical treatments for heart failure (HF), including acute and preventative drugs, and highlights potential new therapies. It notes advances in heart failure with reduced ejection fraction (HFrEF) but a lack of treatments for HF with preserved ejection fraction (HFpEF).

Keywords:

HF with preserved ejection fraction HF with reduced ejection fraction Heart failure Pharmaceutical management

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Related Experiment Videos

Last Updated: Dec 25, 2025

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Area of Science:

Cardiology and Pharmacology
Clinical Medicine

Background:

Heart failure (HF) is a critical clinical syndrome due to impaired ventricular function.
HF is categorized into HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), and HF with midrange ejection fraction (HFmrEF).
Despite progress in HFrEF treatment, HF remains a fatal condition with unmet needs, particularly for HFpEF.

Purpose of the Study:

To review current pharmaceutical management strategies for acute and chronic heart failure.
To summarize major clinical trials in heart failure pharmacotherapy.
To discuss emerging drug candidates and the potential of Traditional Chinese Medicine in HF treatment.

Main Methods:

Literature review of current advances in pharmaceutical management for heart failure.
Summary of key clinical trials for different heart failure classifications.
Inclusion of information on novel therapeutic agents and complementary medicine approaches.

Main Results:

Significant advances have been made in treating HFrEF.
Current pharmaceutical options address acute HF and disease progression.
There remains a notable deficiency in effective treatments for HFpEF.

Conclusions:

The review highlights progress in heart failure pharmacotherapy, especially for HFrEF.
Further research is crucial for developing novel treatments, particularly for HFpEF.
Traditional Chinese Medicine presents a potential avenue for future HF therapies.